What is the story about?
What's Happening?
Leo Cancer Care has successfully raised $40 million in a funding round led by Catalio Capital Management to accelerate the commercialization of its upright radiotherapy system, Marie®. This system, designed for proton therapy, replaces gantry rotation with patient rotation, reducing the size, cost, and complexity of treatment. The Marie® system has received FDA clearance and is set to be installed at leading cancer centers in the U.S., with patient treatments expected later in 2025.
Why It's Important?
The funding secured by Leo Cancer Care highlights the growing recognition of upright radiotherapy's potential to improve patient experiences and expand access to advanced cancer treatments. By reducing the complexity and cost of proton therapy, the Marie® system makes these treatments more accessible and patient-friendly. This innovation represents a significant step forward in cancer care, offering the potential for more efficient and effective treatment options.
What's Next?
With the FDA clearance and funding in place, Leo Cancer Care is poised to begin patient treatments with the Marie® system later in 2025. The company will focus on expanding its installations at cancer centers across the U.S., aiming to make upright radiotherapy a standard option for patients. As the technology becomes more widely available, it is expected to enhance the quality of care and improve outcomes for cancer patients.
AI Generated Content
Do you find this article useful?
